The latest actions follow long-standing litigation in a New Jersey district court, where Arbutus alleges that the two pharmaceutical giants infringed upon five of its U.S. patents. While BioNTech acknowledged the new legal filings, the company declined to comment on its defense strategy. Pfizer did not provide an immediate response to inquiries regarding the suits.
This aggressive legal posture coincides with a recent financial windfall for Arbutus. Earlier this month, the firm secured a $178 million settlement from Moderna to resolve separate patent disputes involving its own Covid-19 vaccine. Bolstered by this influx of capital, Arbutus intends to initiate a share repurchase program in the third quarter, earmarking up to $230 million for the buyback of its common stock.
Comments (0)
No comments yet. Be the first!